181 related articles for article (PubMed ID: 26225729)
1. An inflammatory link in atherosclerosis and obesity. Co-stimulatory molecules.
Zirlik A; Lutgens E
Hamostaseologie; 2015; 35(3):272-8. PubMed ID: 26225729
[TBL] [Abstract][Full Text] [Related]
2. Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis?
Gerdes N; Zirlik A
Thromb Haemost; 2011 Nov; 106(5):804-13. PubMed ID: 21979444
[TBL] [Abstract][Full Text] [Related]
3. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis.
Engel D; Seijkens T; Poggi M; Sanati M; Thevissen L; Beckers L; Wijnands E; Lievens D; Lutgens E
Semin Immunol; 2009 Oct; 21(5):308-12. PubMed ID: 19616449
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory mechanisms in atherosclerosis.
Wolf D; Stachon P; Bode C; Zirlik A
Hamostaseologie; 2014; 34(1):63-71. PubMed ID: 24343521
[TBL] [Abstract][Full Text] [Related]
5. Atherogenesis - tried and tested pieces in the puzzle.
Scharf RE
Hamostaseologie; 2016 May; 36(2):73-4. PubMed ID: 27163332
[No Abstract] [Full Text] [Related]
6. Cytokines and Immune Responses in Murine Atherosclerosis.
Kusters PJ; Lutgens E
Methods Mol Biol; 2015; 1339():17-40. PubMed ID: 26445779
[TBL] [Abstract][Full Text] [Related]
7. Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis.
Bartolini Gritti B; Binder CJ
Hamostaseologie; 2016 May; 36(2):89-96. PubMed ID: 25682990
[TBL] [Abstract][Full Text] [Related]
8. Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice.
Wolf D; Jehle F; Michel NA; Bukosza EN; Rivera J; Chen YC; Hoppe N; Dufner B; Rodriguez AO; Colberg C; Nieto L; Rupprecht B; Wiedemann A; Schulte L; Peikert A; Bassler N; Lozhkin A; Hergeth SP; Stachon P; Hilgendorf I; Willecke F; von Zur Mühlen C; von Elverfeldt D; Binder CJ; Aichele P; Varo N; Febbraio MA; Libby P; Bode C; Peter K; Zirlik A
Circulation; 2014 Jun; 129(23):2414-25. PubMed ID: 24664276
[TBL] [Abstract][Full Text] [Related]
9. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II.
Black PH
Med Hypotheses; 2006; 67(4):879-91. PubMed ID: 16781084
[TBL] [Abstract][Full Text] [Related]
10. Danger signaling in atherosclerosis.
Zimmer S; Grebe A; Latz E
Circ Res; 2015 Jan; 116(2):323-40. PubMed ID: 25593277
[TBL] [Abstract][Full Text] [Related]
11. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
12. Innate immune signals in atherosclerosis.
Lundberg AM; Hansson GK
Clin Immunol; 2010 Jan; 134(1):5-24. PubMed ID: 19740706
[TBL] [Abstract][Full Text] [Related]
13. [Lymphocyte coreceptors].
Olive D
Med Sci (Paris); 2006 Dec; 22(12):1069-74. PubMed ID: 17156728
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the relevance of different mediators in the human immune cell network.
Tieri P; Valensin S; Latora V; Castellani GC; Marchiori M; Remondini D; Franceschi C
Bioinformatics; 2005 Apr; 21(8):1639-43. PubMed ID: 15613387
[TBL] [Abstract][Full Text] [Related]
15. Specialised lipid mediators and their targets.
Crean D; Godson C
Semin Immunol; 2015 May; 27(3):169-76. PubMed ID: 26048571
[TBL] [Abstract][Full Text] [Related]
16. The role of mast cells in atherosclerosis.
Wezel A; Quax PH; Kuiper J; Bot I
Hamostaseologie; 2015; 35(2):113-20. PubMed ID: 25377048
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells in the innate immunity network of atherosclerosis.
Bonaccorsi I; De Pasquale C; Campana S; Barberi C; Cavaliere R; Benedetto F; Ferlazzo G
Immunol Lett; 2015 Nov; 168(1):51-7. PubMed ID: 26384623
[TBL] [Abstract][Full Text] [Related]
18. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis.
Loppnow H; Buerke M; Werdan K; Rose-John S
J Cell Mol Med; 2011 Mar; 15(3):484-500. PubMed ID: 21199323
[TBL] [Abstract][Full Text] [Related]
19. Experimental immunotherapeutic approaches for atherosclerosis.
Amir S; Binder CJ
Clin Immunol; 2010 Jan; 134(1):66-79. PubMed ID: 19666239
[TBL] [Abstract][Full Text] [Related]
20. Targeting the immune response in atherosclerosis: It's time for clinical trials!
Joffre J; Ait-Oufella H
Arch Cardiovasc Dis; 2017 Dec; 110(12):643-645. PubMed ID: 29051009
[No Abstract] [Full Text] [Related]
[Next] [New Search]
